Anonymous
Guest
Anonymous
Guest
It will be interesting if leadership takes time out of the General Session to mention the turmoil that our fellow Novartis reps are going thru in the General Medicine side of the business...last year, there was not enough sensitivity around this issue when many of our Oncology folks were let go....lets see if they are any more communicative this time around.